Compare AVD & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVD | LCTX |
|---|---|---|
| Founded | 1969 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Agricultural Chemicals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.4M | 301.7M |
| IPO Year | 1995 | 1996 |
| Metric | AVD | LCTX |
|---|---|---|
| Price | $2.24 | $1.01 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $12.00 | $6.25 |
| AVG Volume (30 Days) | 311.5K | ★ 846.4K |
| Earning Date | 03-16-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 61.11 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $515,114,000.00 | $14,556,000.00 |
| Revenue This Year | $8.82 | $109.40 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 53.24 |
| 52 Week Low | $2.03 | $1.00 |
| 52 Week High | $5.92 | $2.09 |
| Indicator | AVD | LCTX |
|---|---|---|
| Relative Strength Index (RSI) | 45.67 | 37.52 |
| Support Level | $2.15 | N/A |
| Resistance Level | $2.67 | $1.18 |
| Average True Range (ATR) | 0.12 | 0.05 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 32.08 | 10.81 |
American Vanguard Corp is a United States-based diversified specialty and agricultural products company. The company is a manufacturer of specialty solutions that develops and markets safe synthetic, biological, and biorational products for agricultural, commercial, and consumer uses. These chemicals include insecticides, fungicides, herbicides, molluscicides, growth regulators, and soil fumigants, which are marketed in liquid, powder, and granular forms.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.